Kirby Institute/UNSW – 21 February 2017
More Australians were treated for their hepatitis C infection in the first year new generation hepatitis C regimens were made available on the Pharmaceutical Benefits Schemes than in the past decade, according to a new report released today by the Kirby Institute at UNSW Sydney.
Read more here
Download report (PDF) here
Hepatitis NSW, 2016 This is a really exciting time if you live in Australia and have hep C. The Federal government has announced that new direct acting antiviral (DAA) treatment drugs will be free and available to you from 1 March 2016. The new treatments are: Harvoni® (sofosbuvir/ledipasvir) two drugs combined in each pill Sovaldi® and Daklinza® (sofosbuvir and daclatasvir) separate pills, taken...
Hepatitis SA, April 2015
The Pharmaceutical Benefit Advisory Committee has recommended three new drugs for treatment of hepatitis C.
Read more here